• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Organon & Co. Common Stock (NY: OGN )

    14.58 +0.14 (+0.97%)
    Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 31,638,804
    Open 14.54
    Bid (Size) 14.55 (1)
    Ask (Size) 14.68 (5)
    Prev. Close 14.44
    Today's Range 14.41 - 14.91
    52wk Range 13.65 - 23.10
    Shares Outstanding N/A
    Dividend Yield 7.68%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
    From Organon & Co.
    Via Business Wire
    FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
    From Organon & Co.
    Via Business Wire

    Performance

    YTD
    -0.88%
    -0.88%
    1 Month
    -4.58%
    -4.58%
    3 Month
    -26.06%
    -26.06%
    6 Month
    -30.97%
    -30.97%
    1 Year
    +3.18%
    +3.18%

    More News

    Read More
    Looking Into Organon's Recent Short Interest
    Via Benzinga
    Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
    From Organon & Co.
    Via Business Wire
    P/E Ratio Insights for Organon
    Via Benzinga
    3 Cheap High Dividend Stocks For Passive Income
    Via Talk Markets
    Organon Reports Results for the Third Quarter Ended September 30, 2024
    From Organon & Co.
    Via Business Wire
    US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
    From Organon & Co.
    Via Business Wire
    Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Organon & Co.
    Via Business Wire
    Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Roivant Sciences
    Via GlobeNewswire
    Want $300 in Dividends Every Month? Invest $20,000 in Each of These 3 Stocks
    Via The Motley Fool
    Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
    Via Benzinga
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
    From Organon & Co.
    Via Business Wire
    Organon, Howmet Aerospace And More: CNBC's 'Final Trades'
    Via Benzinga
    Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
    From Organon & Co.
    Via Business Wire
    Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
    Via Talk Markets
    Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
    Via Benzinga
    Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Organon & Co.
    Via Business Wire
    Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
    From Roivant Sciences
    Via GlobeNewswire
    JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
    Via Benzinga
    Organon Stock Sees Relative Strength Rating Rise To 91
    Via Investor's Business Daily
    Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
    Via Investor's Business Daily
    Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
    From Organon & Co.
    Via Business Wire
    OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.